Unknown

Dataset Information

0

Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M2R Affinity and Selectivity.


ABSTRACT: In search for selective ligands for the muscarinic acetylcholine receptor (MR) subtype M2, the dimeric ligand approach, that is combining two pharmacophores in one and the same molecule, was pursued. Different types (agonists, antagonists, orthosteric, and allosteric) of monomeric MR ligands were combined by various linkers with a dibenzodiazepinone-type MR antagonist, affording five types of heterodimeric compounds ("DIBA-xanomeline," "DIBA-TBPB," "DIBA-77-LH-28-1," "DIBA-propantheline," and "DIBA-4-DAMP"), which showed high M2R affinities (pKi > 8.3). The heterodimeric ligand UR-SK75 (46) exhibited the highest M2R affinity and selectivity [pKi (M1R-M5R): 8.84, 10.14, 7.88, 8.59, and 7.47]. Two tritium-labeled dimeric derivatives ("DIBA-xanomeline"-type: [3H]UR-SK71 ([3H]44) and "DIBA-TBPB"-type: [3H]UR-SK59 ([3H]64)) were prepared to investigate their binding modes at hM2R. Saturation-binding experiments showed that these compounds address the orthosteric binding site of the M2R. The investigation of the effect of various allosteric MR modulators [gallamine (13), W84 (14), and LY2119620 (15)] on the equilibrium (13-15) or saturation (14) binding of [3H]64 suggested a competitive mechanism between [3H]64 and the investigated allosteric ligands, and consequently a dualsteric binding mode of 64 at the M2R.

SUBMITTER: She X 

PROVIDER: S-EPMC6044897 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Heterodimerization of Dibenzodiazepinone-Type Muscarinic Acetylcholine Receptor Ligands Leads to Increased M<sub>2</sub>R Affinity and Selectivity.

She Xueke X   Pegoli Andrea A   Mayr Judith J   Hübner Harald H   Bernhardt Günther G   Gmeiner Peter P   Keller Max M  

ACS omega 20171016 10


In search for selective ligands for the muscarinic acetylcholine receptor (MR) subtype M<sub>2</sub>, the dimeric ligand approach, that is combining two pharmacophores in one and the same molecule, was pursued. Different types (agonists, antagonists, orthosteric, and allosteric) of monomeric MR ligands were combined by various linkers with a dibenzodiazepinone-type MR antagonist, affording five types of heterodimeric compounds ("DIBA-xanomeline," "DIBA-TBPB," "DIBA-77-LH-28-1," "DIBA-propantheli  ...[more]

Similar Datasets

| S-EPMC7650007 | biostudies-literature
| S-EPMC6733798 | biostudies-literature
| S-EPMC9126879 | biostudies-literature
| S-EPMC3899540 | biostudies-literature
2022-05-06 | GSE201885 | GEO
| S-EPMC6862617 | biostudies-literature
| S-EPMC2884600 | biostudies-literature
2024-05-22 | PXD042562 | Pride
| S-EPMC3980162 | biostudies-literature
| S-EPMC6270666 | biostudies-literature